888-416-9305 info@abterrabio.com

Digital Proteomics is now Abterra Biosciences

Abterra Biosciences discovers fully human antibodies from patients

Truly human antibody therapeutics.

Humans mount lasting antibody responses to infectious diseases and cancer. Abterra Bio uses next-generation sequencing, mass spectrometry, and machine learning to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.

Abterra Bio technology is built on decades of experience in antibody sequencing and analysis. Click on the services below to see how we can help you!

Abterra Bio Reptor Hybridoma Sequencing


Next-Gen Sequencing Hybridoma

Abterra Bio Reptor Bulk B Cell Sequencing


Next-Gen Sequencing Bulk B Cells
Abterra Bio Reptor Hit Expansion


Next-Gen Sequencing Hit Expansion 
Abterra Bio Reptor Library Sequencing


Next-Gen Sequencing Display Library
Abterra Bio Alicanto Rabbit Antibody Discovery


Rabbit Monoclonal Antibody Discovery
Abterra Bio Alicanto Single Domain Antibody Discovery


Single Domain (VHH) Antibody Discovery

Abterra Bio Alicanto Human Antibody Discovery


Human Antibody Discovery
Abterra Bio Valens Sequence Confirmation


Protein Sequence Confirmation
Abterra Bio Valens Antibody Protein Sequencing


Antibody Protein Sequencing

Our partners’ success means everything to us

I have had great experiences using Abterra Bio’s Reptor platform. The data generated was highly valuable, and the team provided quick and open communication throughout the whole process.

Sandeep Kumar, PhD

Associate Director - Antibody Discovery & Engineering, Scholar Rock

Latest News

Problem Solvers by Nature

"When @necastellana began applying algorithms for protein analysis, she realized that most methods did not utilize the power of the human body’s adaptive immune system." Read about how to unlock the power of the human immune system using bioinformatics. 

Alicanto Innovative New Product Award Finalist

We’re thrilled to announce that Alicanto® was selected as a finalist in CONNECT’s Most Innovative New Product Awards. CONNECT, a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences sectors,...

Phase 1 SBIR Award-Quorum Cloud

Quorum Cloud® is a computational platform that organizes tandem MS data into molecular networks. Molecular networks connect related compounds that differ by a mutation, modification, or adduct. Quorum Cloud® increases NP compound annotations compared to previous...

Scientific Updates

Llama Immune Repertoire Profiling

Alicanto® is Abterra Biosciences' proprietary antibody discovery platform that mines the entire immune response to identify diverse, functional antibodies. For an overview of the proteogenomic process, read more about Alicanto®. The infographic below was created using...

Alicanto Antibody Discovery – Diversity

Alicanto® is Abterra Biosciences' proprietary antibody discovery platform that mines the entire immune response to identify diverse, functional antibodies. For an overview of the proteogenomic process, read more about Alicanto®. Alicanto benefits include: Full...

Antibody Reference Guide

We developed a one-sheet antibody reference that is handy for antibody-related work. We refer to it often to remind ourselves of the major antibody isotypes, antibody fragments, and purification strategies, as well as antibody development processes. Below we outline...

Next Generation Sequencing-Enhanced Antibody Discovery

Using Reptor for NGS-enhanced antibody discoveryTraditional antibody discovery methods, such as hybridoma and phage display, as well as newer single cell screening methods, capture only a small portion of the adaptive immune response, and as a result isolate a small...

Social Media Posts

Meet @necastellana! The UCSD CSE graduate and CEO of @AbterraBio believed that computer science, in conjunction with other scientific fields, had a critical role to play in ameliorating the global health crisis.

Read her feature story : https://bit.ly/3ANcAcl

Don’t miss the chance to recover your lost hybridoma for free!! Sign up for our case study: https://lnkd.in/gm8H8diy
Read more on our de novo sequencing approach and how it can be used to solve your problem!
#biopharma #sequencing

Load More...

Every day, we strive to help our partners and collaborators push the boundaries of their science.

Subscribe To Our Newsletter!

Don't miss out on the latest case studies, posters, and other news.

You have Successfully Subscribed!